The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

Yue-Lun Zhang, Jin-Qiu Yuan, Kai-Feng Wang, Xiao-Hong Fu, Xiao-Ran Han, Diane Threapleton, Zu-Yao Yang, Chen Mao, Jin-Ling Tang, Yue-Lun Zhang, Jin-Qiu Yuan, Kai-Feng Wang, Xiao-Hong Fu, Xiao-Ran Han, Diane Threapleton, Zu-Yao Yang, Chen Mao, Jin-Ling Tang

Abstract

Objectives: Estimate the epidermal growth factor receptor (EGFR) mutation prevalence in all non-small cell lung cancer (NSCLC) patients and patient subgroups.

Results: A total of 456 studies were included, reporting 30,466 patients with EGFR mutation among 115,815 NSCLC patients. The overall pooled prevalence for EGFR mutations was 32.3% (95% CI 30.9% to 33.7%), ranging from 38.4% (95% CI: 36.5% to 40.3%) in China to 14.1% (95% CI: 12.7% to 15.5%) in Europe. The pooled prevalence of EGFR mutation was higher in females (females vs. males: 43.7% vs. 24.0%; OR: 2.7, 95% CI: 2.5 to 2.9), non-smokers (non-smokers vs. past or current smokers: 49.3% vs. 21.5%; OR: 3.7, 95% CI: 3.4 to 4.0), and patients with adenocarcinoma (adenocarcinoma vs. non-adenocarcinoma: 38.0% vs. 11.7%; OR: 4.1, 95% CI: 3.6 to 4.8).

Materials and methods: PubMed, EMBASE, and the Cochrane Library were searched to June 2013. Eligible studies reported EGFR mutation prevalence and the association with at least one of the following factors: gender, smoking status and histology. Random-effects models were used to pool EGFR mutation prevalence data.

Conclusion: This study provides the exact prevalence of EGFR mutations in different countries and NSCLC patient subgroups.

Keywords: epidermal growth factor receptor; meta-analysis; non-small cell lung cancer; prevalence; systematic review.

Conflict of interest statement

CONFLICTS OF INTEREST

All authors declare that there are no conflicts of interest.

Figures

Figure 1. The flow chart of study…
Figure 1. The flow chart of study selection
This figure provides detailed information for the study inclusion and exclusion.

References

    1. International Agency for Research on Cancer, World Health Organization . GLOBOCAN: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012. IARC; 2014.
    1. National Comprehensive Cancer Network Non-small cell lung cancer. 2015 Accessed Apr 13, 2015.
    1. Non-Small Cell Lung Cancer Collaborative Group Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. The Cochrane database of systematic reviews. 2010 CD007309.
    1. Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of non–small-cell lung cancer with erlotinib or gefitinib. New England Journal of Medicine. 2011;364:947–955.
    1. Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine. 2009;361:947–957.
    1. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. New England Journal of Medicine. 2010;362:2380–2388.
    1. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. The lancet oncology. 2010;11:121–128.
    1. Han J-Y, Park K, Kim S-W, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. Journal of Clinical Oncology. 2012;30:1122–1128.
    1. Sequist LV, Yang JC-H, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai C-M, Boyer M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Journal of Clinical Oncology. 2013;31:3327–3334.
    1. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. The lancet oncology. 2012;13:239–246.
    1. Zhou C, Wu Y-L, Chen G, Feng J, Liu X-Q, Wang C, Zhang S, Wang J, Zhou S, Ren S. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. The lancet oncology. 2011;12:735–742.
    1. Zhou C, Wu Y, Chen G, Feng J, Liu X, Wang C, Zhang S, Wang J, Zhou S, Ren S. Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC). ASCO Annual Meeting Proceedings; Paper presented at: ASCO Annual Meeting Proceedings 2011; 2011. p. 7520.
    1. Rosell R, Gervais R, Vergnenegre A, Massuti B, Felip E, Cardenal F, Garcia Gomez R, Pallares C, Sanchez J, Porta R. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. Journal of clinical oncology. 2011;29:abs7503.
    1. Cohen MH, Johnson JR, Chen Y-F, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva®) tablets. The oncologist. 2005;10:461–466.
    1. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839)(Iressa®) tablets. The oncologist. 2003;8:303–306.
    1. Gefitinib approved for use in South Korea Inpharma Wkly. 2003:1398–22.
    1. Roche Tarceva approved for lung cancer in Japan 2007. Accessed Nov 23, 2015.
    1. China Food Drug Administration CFDA drug approval for gefitinib. 2014 Accessed Nov 24, 2015.
    1. U.S. Food and Drug Administration FDA approves targeted therapy for first-line treatment of patients with a type of metastatic lung cancer. 2015 Accessed Nov 24, 2015.
    1. Azzoli CG, Temin S, Aliff T, Baker S, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L. 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non–small-cell lung cancer. Journal of Clinical Oncology. 2011;29:3825–3831.
    1. Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, Hirsch FR, Grunenwald D, Popper H, Smit E. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. Journal of Thoracic Oncology. 2010;5:1706–1713.
    1. Haneda H, Sasaki H, Lindeman N, Kawano O, Endo K, Suzuki E, Shimizu S, Yukiue H, Kobayashi Y, Yano M. A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma. Japanese journal of clinical oncology. 2006;36:69–75.
    1. Chou T-Y, Chiu C-H, Li L-H, Hsiao C-Y, Tzen C-Y, Chang K-T, Chen Y-M, Perng R-P, Tsai S-F, Tsai C-M. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non–small cell lung cancer. Clinical cancer research. 2005;11:3750–3757.
    1. Tsao M-S, Sakurada A, Cutz J-C, Zhu C-Q, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M. Erlotinib in lung cancer—molecular and clinical predictors of outcome. New England Journal of Medicine. 2005;353:133–144.
    1. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non–small-cell lung cancer. Journal of the National Cancer Institute. 2005;97:643–655.
    1. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non–small-cell lung cancer with postoperative recurrence. Journal of Clinical Oncology. 2005;23:2513–2520.
    1. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A. EGFR mutations in non–small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. Journal of Clinical Oncology. 2005;23:857–865.
    1. Han S-W, Kim T-Y, Hwang PG, Jeong S, Kim J, Choi IS, Oh D-Y, Kim JH, Kim D-W, Chung DH. Predictive and prognostic impact of epidermal growth factor receptor mutation in non–small-cell lung cancer patients treated with gefitinib. Journal of clinical oncology. 2005;23:2493–2501.
    1. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. Journal of the National Cancer Institute. 2005;97:339–346.
    1. Jänne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non–small-cell lung cancer: Implications for treatment and tumor biology. Journal of Clinical Oncology. 2005;23:3227–3234.
    1. Shi Y, Au JS-K, Thongprasert S, Srinivasan S, Tsai C-M, Khoa MT, Heeroma K, Itoh Y, Cornelio G, Yang P-C. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non–small-cell lung cancer of adenocarcinoma histology (PIONEER) Journal of Thoracic Oncology. 2014;9:154.
    1. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer biological and clinical implications. Cancer research. 2004;64:8919–8923.
    1. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer. 2007;7:169–181.
    1. Dearden S, Stevens J, Wu Y-L, Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) Annals of Oncology. 2013:mdt205.
    1. Szumera-Ciećkiewicz A, Olszewski WT, Tysarowski A, Kowalski DM, Głogowski M, Krzakowski M, Siedlecki JA, Wągrodzki M, Prochorec-Sobieszek M. EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence. International journal of clinical and experimental pathology. 2013;6:2800.
    1. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII) American journal of cancer research. 2015;5:2892.
    1. Wang S, Wang Z. EGFR mutations in patients with non-small cell lung cancer from mainland China and their relationships with clinicopathological features: a meta-analysis. International journal of clinical and experimental medicine. 2014;7:1967.
    1. Ren JH, He WS, Yan GL, Jin M, Yang KY, Wu G. EGFR mutations in non-small-cell lung cancer among smokers and non-smokers: A meta-analysis. Environmental and molecular mutagenesis. 2012;53:78–82.
    1. Ueno T, Toyooka S, Suda K, Soh J, Yatabe Y, Miyoshi S, Matsuo K, Mitsudomi T. Impact of age on epidermal growth factor receptor mutation in lung cancer. Lung Cancer. 2012;78:207–211.
    1. D'Angelo SP, Pietanza MC, Johnson ML, Riely GJ, Miller VA, Sima CS, Zakowski MF, Rusch VW, Ladanyi M, Kris MG. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. Journal of Clinical Oncology. 2011;29:2066–2070.
    1. Girard N, Sima C, Jackman DM, Sequist LV, Chen H, Yang J-H, Ji H, Waltman B, Rosell R, Taron M. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. European Respiratory Journal. 2012;39:366–372.
    1. Wang M, Zhang X, Zhang X, Zhang L, Zhong W, Xu L, Li L. Efficacy and safety of erlotinib as monotherapy for advanced non-small cell lung cancer. Acta Academiae Medicinae Sinicae. 2010;32:151–156.
    1. Shi Y, Li J, Zhang S, Wang M, Yang S, Li N, Wu G, Liu W, Liao G, Cai K. Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology–Mainland China Subset Analysis of the PIONEER study. PloS one. 2015;10:e0143515.
    1. Leighl NB, Rekhtman N, Biermann WA, Huang J, Mino-Kenudson M, Ramalingam SS, West H, Whitlock S, Somerfield MR. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American society of clinical oncology endorsement of the college of american pathologists/international society for the study of lung cancer/association of molecular pathologists guideline. Journal of Clinical Oncology. 2014:JCO. 2014:2057–3055.
    1. de Lima Lopes G, Segel JE, Tan DS, Do YK, Mok T, Finkelstein EA. Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer. 2012;118:1032–1039.
    1. Salto-Tellez M, Tsao M-S, Shih J-Y, Thongprasert S, Lu S, Chang G-C, Au JS-K, Chou T-Y, Lee J-S, Shi Y-K. Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach. Journal of Thoracic Oncology. 2011;6:1663–1669.
    1. Qian X, Liu J, Sun Y, Wang M, Lei H, Luo G, Liu X, Xiong C, Liu D, Liu J. Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer. Oncotarget. 2016;7:29154–29165. doi: 10.18632/oncotarget.8684.
    1. Xue C, Hu Z, Jiang W, Zhao Y, Xu F, Huang Y, Zhao H, Wu J, Zhang Y, Zhao L. National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China. Lung Cancer. 2012;77:371–375.
    1. Choi Y-L, Sun J-M, Cho J, Rampal S, Han J, Parasuraman B, Guallar E, Lee G, Lee J, Shim YM. EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital. PloS one. 2013;8:e56011.
    1. Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, Tsuruyama T, Travis WD, Date H, Haga H. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. Journal of Thoracic Oncology. 2013;8:52–61.
    1. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled clinical trials. 1986;7:177–188.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi